Abstract
Purpose of review To determine usefulness and versatility of hydrochlorothiazide (HCTZ) relative to other thiazide diuretics in the treatment of hypertension. Recent findings HCTZ was found to be less potent in lowering blood pressure (BP) than other thiazide diuretics, including chlorthalidone (CTD) and bendroflumethiazide. A recent meta-analysis also suggested HCTZ (12.5-25mg daily) to be less potent than antihypertensive agents from several other classes, including angiotensinconverting enzyme inhibitors, angiotensin-receptor blockers, and calcium antagonists. The risk of hyponatremia, hypokalemia, and hyperuricemia associated with HCTZ was lower than with CTD, while the risk of gouty arthritis was similar. Despite lower risks of metabolic side-effects, meta-analysis of clinical trials showed that, for any given difference in achieved clinic SBP, HCTZ therapy was associated with 18% higher adverse cardiovascular events when compared with CTD. Summary Increasing evidence suggests inferiority of HCTZ in lowering BP and cardiovascular outcomes in hypertensive patients when compared with other drugs in the same class, particularly CTD and indapamide. Thus, HCTZ is neither more useful nor more versatile than other thiazide diuretics. CTD and indapamide should be preferred over HCTZ in most hypertensive patients when diuretics are required for treatment of hypertension.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 361-365 |
| Number of pages | 5 |
| Journal | Current Opinion in Cardiology |
| Volume | 30 |
| Issue number | 4 |
| DOIs | |
| State | Published - Aug 24 2015 |
Fingerprint
Keywords
- Chlorthalidone
- Hydrochlorothiazide
- Hypertension
- Thiazide diuretics
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
Hydrochlorothiazide is not the most useful nor versatile thiazide diuretic. / Vongpatanasin, Wanpen.
In: Current Opinion in Cardiology, Vol. 30, No. 4, 24.08.2015, p. 361-365.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Hydrochlorothiazide is not the most useful nor versatile thiazide diuretic
AU - Vongpatanasin, Wanpen
PY - 2015/8/24
Y1 - 2015/8/24
N2 - Purpose of review To determine usefulness and versatility of hydrochlorothiazide (HCTZ) relative to other thiazide diuretics in the treatment of hypertension. Recent findings HCTZ was found to be less potent in lowering blood pressure (BP) than other thiazide diuretics, including chlorthalidone (CTD) and bendroflumethiazide. A recent meta-analysis also suggested HCTZ (12.5-25mg daily) to be less potent than antihypertensive agents from several other classes, including angiotensinconverting enzyme inhibitors, angiotensin-receptor blockers, and calcium antagonists. The risk of hyponatremia, hypokalemia, and hyperuricemia associated with HCTZ was lower than with CTD, while the risk of gouty arthritis was similar. Despite lower risks of metabolic side-effects, meta-analysis of clinical trials showed that, for any given difference in achieved clinic SBP, HCTZ therapy was associated with 18% higher adverse cardiovascular events when compared with CTD. Summary Increasing evidence suggests inferiority of HCTZ in lowering BP and cardiovascular outcomes in hypertensive patients when compared with other drugs in the same class, particularly CTD and indapamide. Thus, HCTZ is neither more useful nor more versatile than other thiazide diuretics. CTD and indapamide should be preferred over HCTZ in most hypertensive patients when diuretics are required for treatment of hypertension.
AB - Purpose of review To determine usefulness and versatility of hydrochlorothiazide (HCTZ) relative to other thiazide diuretics in the treatment of hypertension. Recent findings HCTZ was found to be less potent in lowering blood pressure (BP) than other thiazide diuretics, including chlorthalidone (CTD) and bendroflumethiazide. A recent meta-analysis also suggested HCTZ (12.5-25mg daily) to be less potent than antihypertensive agents from several other classes, including angiotensinconverting enzyme inhibitors, angiotensin-receptor blockers, and calcium antagonists. The risk of hyponatremia, hypokalemia, and hyperuricemia associated with HCTZ was lower than with CTD, while the risk of gouty arthritis was similar. Despite lower risks of metabolic side-effects, meta-analysis of clinical trials showed that, for any given difference in achieved clinic SBP, HCTZ therapy was associated with 18% higher adverse cardiovascular events when compared with CTD. Summary Increasing evidence suggests inferiority of HCTZ in lowering BP and cardiovascular outcomes in hypertensive patients when compared with other drugs in the same class, particularly CTD and indapamide. Thus, HCTZ is neither more useful nor more versatile than other thiazide diuretics. CTD and indapamide should be preferred over HCTZ in most hypertensive patients when diuretics are required for treatment of hypertension.
KW - Chlorthalidone
KW - Hydrochlorothiazide
KW - Hypertension
KW - Thiazide diuretics
UR - http://www.scopus.com/inward/record.url?scp=84942603045&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84942603045&partnerID=8YFLogxK
U2 - 10.1097/HCO.0000000000000178
DO - 10.1097/HCO.0000000000000178
M3 - Article
C2 - 26049382
AN - SCOPUS:84942603045
VL - 30
SP - 361
EP - 365
JO - Current Opinion in Cardiology
JF - Current Opinion in Cardiology
SN - 0268-4705
IS - 4
ER -